Tacrolimus (Topical)
Brand names: Protopic
A topical calcineurin inhibitor (ointment) used as a steroid-sparing treatment for moderate-to-severe atopic eczema, particularly on sensitive sites such as the face and flexures.
Adult dose
Paediatric dose
Dose adjustments
Not stated for the ointment — no renal-impairment dosing statement appears in any fetched section of the Protopic SPC (§4.2 including its Special populations text, §4.3, §4.4, §4.6, §4.8). The renal material in this bundle (nephrotoxicity monitoring, dose reduction) belongs to the US ORAL tacrolimus extended-release capsule label for transplantation and has deliberately not been applied to topical treatment.
Not stated for the ointment — no hepatic-impairment dosing statement appears in any fetched section of the Protopic SPC. The only hepatic-impairment rule in this bundle, 'Patients with severe hepatic impairment (Child-Pugh ≥ 10) may require a lower starting dosage', is from the US ORAL tacrolimus extended-release capsule label (§2.3) and does not apply to the topical ointment.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- §4.3, verbatim: 'Hypersensitivity to the active substance, macrolides in general, or to any of the excipients listed in section 6.1.'
- Not a contraindication but an age limit (§4.2, verbatim): 'Protopic ointment should not be used in children aged below 2 years until further data are available.'
- Not a contraindication but a §4.4 bar, verbatim: 'Protopic should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that cause immunosuppression.'
- Not a contraindication but a §4.4 bar, verbatim: 'Protopic ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant.'
- Not a contraindication but a §4.4 caution, verbatim: 'The use of tacrolimus ointment is not recommended in patients with a skin barrier defect, such as Netherton's syndrome, lamellar ichthyosis, generalized erythroderma, pyoderma gangrenosum or cutaneous Graft Versus Host Disease. These skin conditions may increase systemic absorption of tacrolimus.'
- Not a contraindication but a §4.4 restriction, verbatim: 'Exposure of the skin to sunlight should be minimised and the use of ultraviolet (UV) light from a solarium, therapy with UVB or UVA in combination with psoralens (PUVA) should be avoided during use of Protopic ointment.'
- Not a contraindication but a §4.2 administration restriction, verbatim: 'Protopic ointment should not be applied under occlusion' and it must not be applied to mucous membranes.
Side effects
- §4.8 summary, verbatim: 'In clinical studies approximately 50% of patients experienced some type of skin irritation adverse reaction at the site of application. Burning sensation and pruritus were very common, usually mild to moderate in severity and tended to resolve within one week of starting treatment. Erythema was a common skin irritation adverse reaction. Sensation of warmth, pain, paraesthesia and rash at the site of application were also commonly observed.'
- Very common (≥1/10), §4.8 table: application site burning; application site pruritus
- Common (≥1/100 to <1/10), §4.8: alcohol intolerance (facial flushing or skin irritation after consumption of an alcoholic beverage); paraesthesias and dysaesthesias (hyperaesthesia, burning sensation); pruritus; application site warmth, erythema, pain, irritation, paraesthesia and rash
- Local skin infection regardless of specific aetiology, §4.8 — 'including but not limited to: Eczema herpeticum, Folliculitis, Herpes simplex, Herpes virus infection, Kaposi's varicelliform eruption'; §4.8 also notes 'Patients may be at an increased risk of folliculitis, acne and herpes viral infections'
- Reported during post-marketing experience (asterisked in the §4.8 table): acne, rosacea, lentigo, application site oedema, ophthalmic herpes infection, and 'Drug level increased' (increased tacrolimus blood level)
- Uncommon, §4.4: 'Lymphadenopathy was uncommonly (0.8%) reported in clinical trials. The majority of these cases were related to infections (skin, respiratory tract, tooth) and resolved with appropriate antibiotic therapy.'
- Maintenance (twice-weekly) treatment, §4.8: 'application site impetigo (7.7% in children) and application site infections (6.4% in children and 6.3% in adults)' occurred more frequently than in the control group
- Paediatric population, §4.8, verbatim: 'Frequency, type and severity of adverse reactions in children are similar to those reported in adults.'
- CAVEAT ON FREQUENCIES: the §4.8 frequency table was flattened during the fetch, so column boundaries (very common / common / uncommon / not known) are ambiguous for some rows. The frequency labels used above are taken from the unambiguous §4.8 narrative text and from asterisk footnotes; check the table itself in the SPC before quoting a frequency.
Monitoring
- §4.2, verbatim: 'Generally, improvement is seen within one week of starting treatment. If no signs of improvement are seen after two weeks of treatment, further treatment options should be considered.'
- §4.2 (maintenance, adults), verbatim: 'After 12 months treatment, a review of the patient`s condition should be conducted by the physician and a decision taken whether to continue maintenance treatment in the absence of safety data for maintenance treatment beyond 12 months.'
- §4.2 (maintenance, children), verbatim: 'The review of the child`s condition after 12 months treatment should include suspension of treatment to assess the need to continue this regimen and to evaluate the course of the disease.'
- §4.4, verbatim: 'Patients, particularly paediatric patients should be continuously evaluated during treatment with Protopic with respect to the response to treatment and the continuing need for treatment. After 12 months this evaluation should include suspension of Protopic treatment in paediatric patients.'
- §4.4, verbatim: 'The development of any new change different from previous eczema within a treated area should be reviewed by the physician.'
- §4.4: watch for lymphadenopathy — reported uncommonly (0.8%) in clinical trials, mostly infection-related.
- §4.4: increased tacrolimus blood level has been reported post-marketing in patients with skin-barrier defects (Netherton's syndrome, lamellar ichthyosis, generalized erythroderma, pyoderma gangrenosum, cutaneous GvHD); §4.8 lists 'Drug level increased' as a post-marketing reaction.
- §4.4: counsel on sun protection — 'Physicians should advise patients on appropriate sun protection methods, such as minimisation of the time in the sun, use of a sunscreen product and covering of the skin with appropriate clothing.'
Clinical monograph
How it works
Tacrolimus inhibits calcineurin within T-lymphocytes, blocking the dephosphorylation of NFAT and thereby suppressing transcription of pro-inflammatory cytokines and the cutaneous inflammatory response, without the skin-atrophy effects of corticosteroids.
Prescribing in practice
- A transient burning or stinging sensation at the application site is common in the first days of treatment, and patients should avoid excessive natural or artificial UV exposure (including sunbeds) given a theoretical malignancy concern flagged by the MHRA.
- It is reserved for eczema unresponsive to, or where there is a risk of harm from, conventional topical corticosteroids, and should not be applied to infected or potentially malignant skin lesions.
- Initiation is generally by, or under the guidance of, a prescriber experienced in atopic eczema, with the lower-strength preparation used in children.
Monitoring
No routine blood monitoring is needed; review treatment response and the application site, reassessing if lesions fail to improve or appear infected.
Counselling the patient
- Apply a thin layer to affected skin only and wash hands afterwards unless treating the hands.
- Mild burning or itching when starting usually settles within a few days; alcohol may worsen facial flushing.
- Protect treated skin from strong sunlight and avoid sunbeds while using it.
Evidence & guidelines
Topical tacrolimus is recommended by NICE as a second-line option for atopic eczema not controlled by topical corticosteroids, particularly for the face and neck.
Reference: NICE CG57; BAD Atopic Eczema Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART2 Risk Score for Recurrent Vascular Events · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility (NICE TA393 / TA394) · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD